A nicotine transdermal delivery system (NTDS) designed to deliver 15 mg/16 hours (Nicotrol®) was applied to 40 healthy smoking volunteers in 3 separate studies: A single administration to different body sites, a multiple-dose study with 16-hour repeated application for 6 days, and a single-dose study with a 16-hour versus a 24-hour application period. The resulting plasma nicotine concentration profiles were similar after application to the arm or the hip with maximum nicotine concentrations of approximately 13 µg/L attained after 8 to 10 hours. The nicotine half-life after removal of the patch was approximately 4 hours. When applying the NTDS daily for a 16-hour period, nicotine stored in a shallow skin compartment was emptied during the nonapplication night-time period, and the repeat-dose study over 6 days showed no accumulation of plasma nicotine. Compared with an average nicotine intake of 15 mg/16 hours when applying NTDS according to recommendation, wearing it for 24 hours resulted in an additional nicotine release of only 2 to 3mg. This profile of nicotine release lends support to the idea of Nicotrol® being a daytime (16-hour) delivery system. Pharmacokinetic simulation indicated that the transdermal system itself determines the flux so an increase in cutaneous blood flow would have no major influence on the nicotine plasma concentration-time profile.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
US Surgeon General, 1988
Benowitz NL. Pharmacodynamics of nicotine: implications for rational treatment of nicotine addiction. Br J Addic 1991; 86: 495–9
Peters JA. Nicotine-replacement therapy in cessation of smoking. Mayo Clin Proc 1990; 65: 1619–23
Benowitz NL. Pharmacologic aspects of cigarette smoking and nicotine addiction. N Engl J Med 1988; 319: 1318–30
Rose JE, Jarvik ME, Rose KD. Transdermal administration of nicotine. Drug Alcohol Depend 1984; 13: 209–13
Palmer KJ, Faulds D. Transdermal nicotine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as an aid to smoking cessation. Drugs 1992; 44: 498–529
Benowitz NL. Clinical pharmacology of transdermal nicotine. Eur J Pharm Biopharm 1995; 41(3): 168–74
Ho H, Chien YW. Kinetic evaluation of transdermal nicotine delivery systems. Drug Dev Ind Pharm 1993: 19(3): 295–313
Abelin T, Ehrsam R, Bühler-Reichert A, et al. Effectiveness of a transdermal nicotine system in smoking cessation studies. Methods Find Exp Clin Pharmacol 1989; 11: 205–14
Hurt RD, Lauger GG, Offord KP, et al. Nicotine-replacement therapy with use of a transdermal nicotine patch — a randomized double-blind placebo-controlled trial. Mayo Clin Proc 1990; 65: 1529–37
Rose JE, Levin ED, Behm FM, et al. Transdermal nicotine facilitates smoking cessation. Clin Pharmacol Ther 1990; 47: 323–30
Fagerström KO, Lunell E, Molander L. Continuous and intermittent transdermal delivery of nicotine: blockade of withdrawal symptoms and side effects. J Smoking-Related Dis 1991; 2: 173–80
Molander L, Lunell E, Andersson S-B, et al. Dose released and absolute bioavailability of nicotine from a nicotine vapor inhaler. Clin Pharmacol Ther 1996; 59(4): 394–400
Benowitz NL, Jacob P III, Denaro C, et al. Stable isotope studies of nicotine kinetics and bioavailability. Clin Pharmacol Ther 1991; 49: 270–7
Benowitz NL, Jacob P III, Olsson P, et al. Intravenous nicotine retards transdermal absorption of nicotine evidence of blood flow-limited percutaneous absorption. Clin Pharmacol Ther 1992; 52: 223–30
Fagerström KO, Säwe U, Tönnesen P. Therapeutic use of nicotine patches: efficacy and safety. J Smoking-Related Dis 1992; 3: 247–61
Daughton DM, Heatley SA, Prendergast JJ, et al. Effect of transdermal nicotine delivery as an adjunct to low-intervention smoking cessation therapy. A randomized, placebo controlled, double-blind study. Arch Intern Med 1991; 151: 749–52
About this article
Cite this article
Johansson, CJ., Olsson, P., Gunnarsson, P.O. et al. Pharmacokinetics of a 16-Hour Transdermal Nicotine Patch. Clin. Drug Invest. 12, 198–206 (1996). https://doi.org/10.2165/00044011-199612040-00005
- Adis International Limited
- Stratum Corneum
- Drug Invest
- Nicotine Patch